Krensavage Asset Management, LLC Alkermes Plc. Transaction History

Krensavage Asset Management, LLC

$178 Million
Q3 2024

A detailed history of Krensavage Asset Management, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Krensavage Asset Management, LLC holds 251,495 shares of ALKS stock, worth $7.23 Million. This represents 3.94% of its overall portfolio holdings.

Number of Shares

251,495

Previous 257,554 2.35%

Holding current value

$7.23 Million

Previous $6.21 Million 13.4%

% of portfolio

3.94%

Previous 2.85%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.01 - $28.55 $139,417 - $172,984	-6,059 Reduced 2.35%	251,495 $7.04 Million
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $17.4 Million - $21.5 Million	-660,484 Reduced 71.95%	257,554 $6.97 Million
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $279,925 - $343,529	11,978 Added 1.32%	918,038 $25.5 Million
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $5.36 Million - $6.31 Million	-197,391 Reduced 17.89%	906,060 $25.4 Million
Q2 2023 Aug 11, 2023	SELL	$28.34 - $33.63 $8.29 Million - $9.83 Million	-292,346 Reduced 20.94%	1,103,451 $34.5 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $151,505 - $173,713	-5,986 Reduced 0.43%	1,395,797 $39.3 Million
Q4 2022 Feb 15, 2023	SELL	$21.94 - $26.24 $217,184 - $259,749	-9,899 Reduced 0.7%	1,401,783 $36.6 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $297,506 - $430,978	13,523 Added 0.97%	1,411,682 $31.5 Million
Q2 2022 Aug 16, 2022	SELL	$26.4 - $30.54 $687,588 - $795,414	-26,045 Reduced 1.83%	1,398,159 $41.7 Million
Q1 2022 May 17, 2022	SELL	$23.07 - $27.99 $432,816 - $525,120	-18,761 Reduced 1.3%	1,424,204 $37.5 Million
Q4 2021 Feb 15, 2022	BUY	$21.47 - $32.08 $21,427 - $32,015	998 Added 0.07%	1,442,965 $33.6 Million
Q3 2021 Nov 16, 2021	SELL	$23.37 - $32.13 $5.77 Million - $7.93 Million	-246,874 Reduced 14.62%	1,441,967 $44.5 Million
Q2 2021 Aug 13, 2021	BUY	$18.78 - $25.15 $1.16 Million - $1.55 Million	61,518 Added 3.78%	1,688,841 $41.4 Million
Q1 2021 May 18, 2021	BUY	$18.21 - $23.2 $121,060 - $154,233	6,648 Added 0.41%	1,627,323 $30.4 Million
Q4 2020 Feb 17, 2021	BUY	$15.39 - $22.1 $743,029 - $1.07 Million	48,280 Added 3.07%	1,620,675 $32.3 Million
Q3 2020 Nov 17, 2020	BUY	$16.16 - $20.66 $124,916 - $159,701	7,730 Added 0.49%	1,572,395 $26.1 Million
Q2 2020 Aug 20, 2020	BUY	$13.31 - $19.41 $20.8 Million - $30.4 Million	1,564,664 Added 0.0%	1,564,665 $30.4 Million
Q2 2020 Aug 17, 2020	SELL	$13.31 - $19.41 $15.5 Million - $22.7 Million	-1,167,630 Reduced 100.0%	1 $30.4 Million
Q1 2020 May 18, 2020	BUY	$13.06 - $21.24 $3.43 Million - $5.58 Million	262,553 Added 29.01%	1,167,631 $16.8 Million
Q4 2019 Feb 18, 2020	BUY	$17.29 - $21.74 $15.6 Million - $19.7 Million	905,078 New	905,078 $18.5 Million

Others Institutions Holding ALKS

# of Institutions

363

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.72B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krensavage Asset Management, LLC with notifications on news.

Account

Krensavage Asset Management, LLC Alkermes Plc. Transaction History